Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial (Q38822258)
Jump to navigation
Jump to search
scientific article published on 21 April 2017
Language | Label | Description | Also known as |
---|---|---|---|
English | Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial |
scientific article published on 21 April 2017 |
Statements
1 reference
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial (English)
1 reference
Karen Basen-Engquist
1 reference
Keiichi Fujiwara
1 reference
Robert L Coleman
1 reference
Mark F Brady
1 reference
Thomas J Herzog
1 reference
Paul Sabbatini
1 reference
Deborah K Armstrong
1 reference
Joan L Walker
1 reference
Byoung-Gie Kim
1 reference
Krishnansu S Tewari
1 reference
David M O'Malley
1 reference
Susan A Davidson
1 reference
Stephen C Rubin
1 reference
Paul DiSilvestro
1 reference
Helen Huang
1 reference
John K Chan
1 reference
Nick M Spirtos
1 reference
Raheela Ashfaq
1 reference
Robert S Mannel
1 reference
21 April 2017
1 reference
18
1 reference
6
1 reference
779-791
1 reference
Identifiers
1 reference